Hepatocyte
growth factor (HGF) is secreted by human pancreatic stellate cells and
present predominantly on cancer cells. Thus, HGF inhibitors has emerged as an
effective therapy in preventing local tumor growth. Also, studies have
demonstrated that HGF inhibitors are significantly more effective than
Gemcitabine in inhibiting tumor angiogenesis and metastasis.
Studies have demonstrated that the HGF inhibitor can be a
novel therapeutics that can be developed as a monotherapy or as combination
therapy with RAS-RAF-MEK, AKT-mTOR, and EGFR inhibitors for the treatment of
various human cancers. HGF inhibitors have shown potent antineoplastic effects
in several clinical trials for the treatment of head and neck squamous cell
carcinoma as HGF/c-Met pathway is directly involved in the development of a
proliferative, invasive, and metastatic cancer.
Request to Get the Sample Pages at:
AVEO Pharmaceuticals Inc. is in the process of developing
Ficlatuzumab as a potent HGF inhibitor antibody that binds to the HGF ligand
with high affinity and specificity to inhibit HGF/c-Met biological activities
for the treatment of squamous cell carcinoma of the head and neck and acute
myeloid leukemia. Galaxy Biotech LLC, Daiichi Sankyo Company Limited, and Taiho
Pharmaceutical Co. are some other companies having HGF inhibitor pipeline.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with detailed analysis of pipeline and clinical trials. Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licencing, grants, technology and others.
